Health Condition 1: L732- Hidradenitis suppurativa
Conditions
Interventions
Intervention1: Apremilast: Apremilast
Dose - 30 mg tablet.
Frequency - one tablet twice daily
Route - Oral
Duration - 3 months
Control Intervention1: Doxycycline: Doxycycline
Dose - 100 mg tablet
Sponsors
Post Graduate institute of medical education and research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as HS based on the San Francisco modification of Dessau criteria and severity defined as moderate (stage II) by Hurley staging and HS-PGA score more than 3. 2. Age > 18 years. 3. Patients who can give valid consent. 4. Willing for monthly follow-up visits for at least 3 months.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating mothers 2. Severe hepatic/renal dysfunction 3. Patients with HIV, Hepatitis B and Hepatitis C 4. Inability to come for monthly follow up visits for 3 months 5. Those who cannot provide consent for the study 6. Known case of psychiatric disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| i. To assess the proportion of patients reaching the Hidradenitis Suppurativa Clinical Response (HiSCR) at the end of the study.Timepoint: 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| i. To assess the proportion of patients reaching HiSCR at week 4. ii. To compare the clinical outcome in each group at the end of the study. iii. To compare the functional outcome in each group at the end of the study, as assessed by DLQI. To evaluate the safety profile of apremilast versus doxycycline in moderate HS.Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDipankar De
Post Graduate Institute of Medical Education and Research, Chandigarh
Outcome results
None listed